This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rödel, C. Articles by Sauer, R. Search for Related Content PubMed PubMed Citation Articles by Rödel, C. Articles by Sauer, R. Social Bookmarking                            What's this?

Trimodality Treatment and Selective Organ Preservation for Bladder Cancer

Claus Rödel, Christian Weiss, Rolf Sauer

From the Department of Radiation Therapy, University of Erlangen, Germany

Address reprint requests to Claus Rödel, MD, Department of Radiation Therapy, University of Erlangen, Universitätsstr 27, D-91054 Erlangen, Germany; e-mail: claus.roedel{at}strahlen.med.uni-erlangen.de

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. F. Bajorin, R. J. Motzer, and G. J. Bosl Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481. [Full Text] [PDF]